N-Nitrosovancomycin
N-Nitrosovancomycin is an antibacterial agent and an N-terminal nitrosated derivative of vancomycin. N-Nitrosovancomycin exhibits antibacterial activity against Gram-positive bacteria in vitro, but shows no activity against Gram-negative E. coli. The modified N-terminal amino group of N-Nitrosovancomycin cannot be protonated, yet the compound still retains in vitro antibacterial activity. N-Nitrosovancomycin can be used in studies related to Gram-positive bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 155386-25-7
- Formula: C66H74Cl2N10O25
- Molecular Weight:1478.25
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
N-Nitrosovancomycin (18-24 h) inhibits the growth of multiple Gram-positive clinical isolates in vitro, with MIC50 values ranging from 4.00 to 8.00 μg/mL and MIC90 values ranging from 4.00 to 16.00 μg/mL across the tested strains[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 155386-25-7
-
Molecular Weight 1478.25
-
Formula C66H74Cl2N10O25
-
SMILES
ClC1=CC([C@H]([C@H](C(N[C@H](C(N[C@@]2([H])C(N[C@]3([H])C4=CC=C(O)C(C5=C(O)C=C(O)C=C5[C@H](NC([C@](NC3=O)([H])[C@@H](C6=CC=C(O7)C(Cl)=C6)O)=O)C(O)=O)=C4)=O)=O)CC(N)=O)=O)NC([C@@H](CC(C)C)N(C)N=O)=O)O)=CC=C1OC8=C(C7=CC2=C8)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]%10C[C@](N)([C@@H]([C@@H](O%10)C)O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
References
[1]. Zhou QL, et al. Preparation method of N-nitroso-vancomycin, CN, CN120289581A, 2025-07-11.
[2]. Pavlov AY, et al. Synthesis and biological activity of derivatives of glycopeptide antibiotics eremomycin and vancomycin nitrosated, acylated or carbamoylated at the N-terminal. J Antibiot (Tokyo). 1993;46(11):1731-1739. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- N-Nitrosovancomycin
- 155386-25-7
- Drug Derivative
- Bacterial
- gram-positive bacterial infections
- coagulase-negative staphylococci
- Gram-negative Escherichia coli
- HRMS
- 1H-NMR
- 13C-NMR
- methicillin-resistant Staphylococcus aureus
- Enterococcus species
- methicillin-sensitive Staphylococcus aureus
- Gram-positive bacteria
- Inhibitor
- inhibitor
- inhibit